Provexis PLC
21 March 2007
21 March 2007
PROVEXIS plc
('Provexis' or the 'Company')
GRANT OF US PATENT FOR INFLAMMATORY BOWEL DISEASE TECHNOLOGY
Provexis plc, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that the US Patent Office has granted a
patent for its plantain-based extract for the treatment of Inflammatory Bowel
Disease ('IBD').
Provexis has been developing the plantain-based extract in conjunction with its
partner, the University of Liverpool, with the aim of extending periods of
remission in Crohn's Disease patients. A prototype product is currently
undergoing final testing, and the Company will shortly be applying for
authorisation to commence a large-scale one-year human trial later in 2007.
Stephen Moon, CEO commented:
'We are pleased that the patent for our plantain technology has been granted in
the world's largest market. Preparations for the human trial are now well
advanced and we believe this important element of our pipeline will deliver
significant shareholder value in the future.'
-ends-
For further information please contact:
Stephen Moon, CEO
Provexis plc Tel: 020 8392 6631
Tom Griffiths/Richard Johnson
Arbuthnot Securities Tel: 020 7012 2000
Notes:
Crohn's Disease is a type of IBD affecting 1 in 600 people in the developed
world. Current treatments are expensive, have limited efficacy and can also have
significant side effects. Given the debilitating nature of the disease, an
efficacious and cost effective supplement specifically aimed at the maintenance
of remission should be attractive to the medical profession and Crohn's Disease
sufferers. The fruit of the plantain, which is similar to the banana, contains a
type of soluble fibre with bioactive properties.
This information is provided by RNS
The company news service from the London Stock Exchange